Clinical trial NCT02318511: An Investigation of ReNu™ Knee Injection in Patients With Osteoarthritis
Official title: An Investigation of ReNu™ Knee Injection: Monitoring the Response of Knee Function and Pain in Patients With Osteoarthritis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Osteoarthritis
Lead sponsor: NuTech Medical, Inc
Sponsor class: INDUSTRY
Collaborators: name: Organogenesis
First posted: 2014-12-17
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a Prospective, Randomized study evaluating the efficacy of ReNu for the treatment of Kellgren-Lawrence grade 2 or 3 osteoarthritis. Patients will be randomized into 1 of 3 groups for injection into the effected knee: 1) ReNu - study treatment, 2) Hyaluronic Acid (HA) injection - with commonly used injection material and 3) Saline. After treatment, patients will be followed up to 12 months to evaluate improvements using common pain and function subscales.


Eligibility criteria: Inclusion Criteria:

* Patients with moderate knee osteoarthritis determined by a combination of clinical and radiographic findings and documented by Kellgren-Lawrence radiographic classification (Grade 2 or 3)
* Grade 2 Kellgren-Lawrence radiographic changes are defined as small osteophytes, possible narrowing of joint space
* Grade 3 Kellgren-Lawrence radiographic changes are defined as moderate multiple osteophytes, definite narrowing of joints space, some sclerosis and possible deformity of bone contour.
* Patients with bilateral grade 2 or 3 Kellgren Lawrence knee osteoarthritis who have bilateral symptoms may have their more symptomatic knee injected. If equivalent symptoms are reported by the patient, then the patient will choose which knee is to be injected. The contralateral knee can be treated with local standard of care such as steroid injection, cold therapy or soft brace.
* Age 18 and older
* BMI less than 40
* 7 day average pain score of 4 or greater for the involved knee on a numeric pain scale from 1 to 10.
* Female patients must be actively practicing a contraception method, abstinence, be surgically sterilized, or be postmenopausal

Exclusion Criteria:

* Pain medication (including nonsteroidal antiinflammatory drugs, NSAIDs) less than 15 days before injection (may take acetaminophen)
* Receiving pain medication other than acetaminophen for conditions unrelated to osteoarthritis of the index knee
* Regular use of anticoagulants, such as Coumadin, dabigatran or rivaroxaban; use of antiplatelet medications are not a reason for exclusion
* History of substance abuse.
* Failure to agree NOT to take additional knee symptom modifying drugs, other than acetaminophen, during the course of the study without reporting to the study team
* Pregnancy or desire to become pregnant during study duration
* Positive pregnancy test on premenopausal subject
* Morbid obesity (defined as BMI 40 or greater)
* Symptoms of locking, intermittent block to range of motion or loose body sensation which could indicate meniscal displacement or an intraarticular loose body
* Corticosteroid injection into the index knee within 3 months
* Viscosupplement injection into the index knee within 3 months
* Knee surgery of involved index knee within 12 months
* Knee surgery contralateral knee 6 months
* Worker compensation
* Acute index knee injury (injury within 3 months)
* History of Diabetes mellitus
* History of solid organ or hematologic transplantation
* History of rheumatoid arthritis or other autoimmune disorder
* Diagnosis of a non-basal cell malignancy within the preceding 5 years
* Infection requiring antibiotic treatment within the preceding 3 months
* Current therapy with any immunosuppressive medication, including corticosteroids at a dose \> 5 mg per day

Primary outcomes:
measure: VAS Pain Scale Change from Baseline
timeFrame: 3 months
measure: VAS Pain Scale Change from Baseline
timeFrame: 6 months
measure: KOOS Pain and Function Subscales Change from Baseline
timeFrame: 3 months
measure: KOOS Pain and Function Subscales Change from Baseline
timeFrame: 6 months
Secondary outcomes:
measure: KOOS Pain and Function Subscales change from Baseline
timeFrame: 1 week, 6 weeks, 3 months, and 12 months
measure: Other patient reported outcomes (PROs) change from Baseline
timeFrame: 1 week, 6 week, 3 months, 6 months, and 12 months
measure: Radiographic (X-ray) measurement of standing joint space change from Baseline
timeFrame: 12 months
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: American Sports Medicine Institute
state: Alabama
city: Los Angeles
country: United States
facility: Cedars-Sinai Medical Center
state: California
city: Chicago
country: United States
facility: Midwest Orthopedics at Rush, LLC
state: Illinois
city: Indianapolis
country: United States
facility: Orthoindy
state: Indiana
city: Lexington
country: United States
facility: Center for Clinical and Translational Science UK Chandler Medical Center, Pavilion H
state: Kentucky
city: Chestnut Hill
country: United States
facility: Brigham and Women's Hospital
state: Massachusetts
city: Columbia
country: United States
facility: Missouri Orthopaedic Institute (MOI)
state: Missouri
city: Albuquerque
country: United States
facility: New Mexico Orthopaedics
state: New Mexico
city: New York
country: United States
facility: New York University
state: New York
city: New York
country: United States
facility: Hospital for Special Surgery
state: New York
city: Columbus
country: United States
facility: The Ohio State University
state: Ohio
city: Richmond
country: United States
facility: Advanced Orthopedics
state: Virginia
Study officials:
affiliation: OrthoIndy
name: Jack Farr, MD
role: PRINCIPAL_INVESTIGATOR
References: